Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Camp4 Therapeutics (CAMP) to $12 from $18 and keeps an Overweight rating on the shares. The firm notes Camp4 recently raised $50M bringing pro-form cash to about $86.1M to fund operations into 2027. Participating investors agreed to purchase an additional $50M upon acceptance of the CTA for CPS-SYNGAP-01, which Piper expects in the second half of 2026. The firm is lowering its price target on the shares by increasing value for CMP-SYNGAP-01, reducing value for CMP-CPS-001 and factoring dilution from the recent financing.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP:
- Biotech Alert: Searches spiking for these stocks today
- CAMP4 Therapeutics Secures $100M in Private Placement
- Camp4 Therapeutics announces oversubscribed private placement up to $100M
- Camp4 Therapeutics appoints Doug Williams as board chair, Dan Tardiff as CSO
- CAMP4 Therapeutics Reports Q2 2025 Progress and Outlook